PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1450506-3 1992 Recombinant human alpha-interferon (IFN) at a dose of 3 million units combined with melphalan and prednisolone was administrated. Prednisolone 98-110 interferon alpha 1 Homo sapiens 18-40 6696458-6 1984 IFN therapy combined with other agents, such as adenine arabinoside, prednisolone, etc. Prednisolone 69-81 interferon alpha 1 Homo sapiens 0-3 10063307-2 1999 METHODS: Thirty-two patients with CAH-B were treated with interferon alpha-2b(IFN alpha-2b) with prednisolone withdrawal and 30 control patients were treated with conventional hepatotonics for 6 months. Prednisolone 97-109 interferon alpha 1 Homo sapiens 78-81 10063307-7 1999 The levels of liver function test(LFT) in the patients with IFN alpha-2b treatment with prednisolone withdrawal were not different from the control patient group at pretreatment, but significantly lower than control patient group"s after treatment, regardless of response to IFN alpha-2b treatment with prednisolone withdrawal. Prednisolone 88-100 interferon alpha 1 Homo sapiens 60-63 10063307-7 1999 The levels of liver function test(LFT) in the patients with IFN alpha-2b treatment with prednisolone withdrawal were not different from the control patient group at pretreatment, but significantly lower than control patient group"s after treatment, regardless of response to IFN alpha-2b treatment with prednisolone withdrawal. Prednisolone 303-315 interferon alpha 1 Homo sapiens 60-63 10063307-9 1999 IFN alpha-2b treatment with prednisolone withdrawal may be regarded as one of the effective treatment modalities for the inhibition of disease progression in patients with CAH-B. Prednisolone 28-40 interferon alpha 1 Homo sapiens 0-3 6178505-4 1982 Prednisolone, an inhibitor of phospholipase A2, at a concentration of 2 micrograms/ml inhibited the enhanced synthesis of PGE by IFN-pretreated cells. Prednisolone 0-12 interferon alpha 1 Homo sapiens 129-132 6178505-10 1982 Prednisolone and iodomethacin partially inhibited anti-cell growth activity of IFN, suggesting a possibility that IFN-inhibited cell growth was partly mediated by prostaglandin. Prednisolone 0-12 interferon alpha 1 Homo sapiens 79-82 6178505-10 1982 Prednisolone and iodomethacin partially inhibited anti-cell growth activity of IFN, suggesting a possibility that IFN-inhibited cell growth was partly mediated by prostaglandin. Prednisolone 0-12 interferon alpha 1 Homo sapiens 114-117 16225652-7 2005 In conclusion, continuing prednisolone treatment during the entire duration of the induction phase with VMCP-IFN-alpha 2b did not improve outcome. Prednisolone 26-38 interferon alpha 1 Homo sapiens 109-118 15515704-5 2004 One year later, worsening of his hepatic condition required re-administration of IFN alpha after gradual decrease and discontinuation of prednisolone. Prednisolone 137-149 interferon alpha 1 Homo sapiens 81-90 10845671-1 2000 BACKGROUND/AIMS: The aim of this study was to understand the changes in the proportion of hepatitis B virus precore stop mutant during the course of prednisolone primed interferon (IFN) therapy. Prednisolone 149-161 interferon alpha 1 Homo sapiens 181-184 10845671-2 2000 METHODS: Three groups of patients were included: patients receiving prednisolone-primed IFN treatment (Group I, n=31), IFN treatment only (Group II, n=29), and placebo (Group III, n=25). Prednisolone 68-80 interferon alpha 1 Homo sapiens 88-91 10845671-10 2000 CONCLUSIONS: Our data suggest that prednisolone serves as a modulator to enhance elimination of precore stop mutant by IFN, which advocates the benefit of corticosteroid pretreatment in an area where the precore mutants are prevalent. Prednisolone 35-47 interferon alpha 1 Homo sapiens 119-122